Mercado de tratamiento de la migraña en América del Norte: tendencias de la industria y pronóstico hasta 2030

North America Migraine Treatment Market Analysis and Size

Migraine is largely affecting millions of people globally. Headache accounts for 4.4% of all general practise visits, nearly 5% of all medical hospital admissions, and more than 20% of neurology outpatient consultations. The increased incidence rate of injuries has majorly lifted the growth of the migraine treatment market. Many vendors will invest in migraine medications research and development due to the increasing number of migraine incidences.

Data Bridge Market Research analyses that the migraine treatment market is expected to reach USD 18,327.33 million by 2030, which is USD 7,245.38 million in 2022, and is expected to undergo a CAGR of 12.3% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

North America Migraine Treatment Market Scope and Segmentation

Market Definition

Migraine treatment involves the use of over-the-counter painkillers, such as paracetamol, aspirin and ibuprofen for treating both the migraines (aura and without aura). Migraine is a devastating neurological disease typically characterized by recurrent severe head pain attacks that can last for more than three days. The headaches, which are generally unilateral, can last from four hours to three days.  

North America Migraine Treatment Market Dynamics

Drivers

• Increasing Awareness Programs About Migraine

The increasing awareness programs of migraine by public, non-profit and private organization is expected to boost the market growth. There are numerous programs and initiatives globally for sensitizing and educating the public to minimize the global burden of neurological disorders such as migraine. These initiatives are conducted with an aim to prevent diseases, decrease stigma and prejudice, and promote more research activities. For instance, the migraine trust celebrated the migraine awareness week in August 2019 by sharing six ideas for educating people associated with migraine in the future. Thus, this factor boosts the market growth.

• Rising Prevalence of Migraine

There is a rising incidence of migraine which is impacting the market growth. It is more prevalent in midlife, and rates reduce after age 60 years. Nearly 1% of people in the U.S. experience chronic migraine, which equals 1.5 million women and more than half a million men in the U.S., some of whom survive with migraine daily. According to the Migraine Institute, more than 4 million adults suffer from chronic migraine pain on a regular basis. It has also been witnessed that an individual suffering from chronic migraines experiences at least 15 migraine headache days per month for three months or longer. Thus, it will boost the demand for the migraine treatment, increasing the market growth.

Opportunities

• Increasing Product Launches

There have been increasing launches of drugs for the treatment of migraine which is improving the market growth. For instance, the approval of the U.S. FDA for the new class of drug specially designed for treating migraine has transformed the market positively. The new FDA approved drugs are Aimovig (Erenumab), Emgality and Ajovy. Eli Lilly and Company received the U.S. Food and Drug Administration approval for Emgality (galcanezumab-gnlm) in 2020. It is a 120 mg injection used for the preventive treatment of migraine in adults. Thus, increasing product launches boost the growth of the market.

• Growing Adoption of Preventive/Prophylactic Treatment

Preventive or prophylactic treatment includes prescription of off-label and generic medications which includes beta-blockers such as anti-epileptics such as topiramate, atenolol and propranolol, and divalproex sodium. Presently, Allergan’s Botox (neurotoxin), Amgen/ Novartis’s Aimovig, and Teva’s Ajovy (CGRP mAb) are the only drugs which are approved for migraine prevention. Botox requires more than 30 injections across the forehead, shoulders, and neck and yet does not relieve episodic migraine. Thus, this factor enhances the market growth rate.

Restraints/Challenges

• Side-Effects of Migraine Medications

There are various adverse effects that are associated with migraine that impedes the growth of the market. Effects such as tingling, sleepiness, dizziness, chest pain, flushing and other effects which hampers the adoption of migraine drugs by patients. This factor is anticipated to limit the market growth.

This migraine treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the migraine treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In 2020, Abbott launched IonicRF Generator. The IonicRF Generator is a minimally invasive device that uses heat to target specific nerves for chronic pain management.  It is a radiofrequency ablation device that uses heat to restrict pain signals from reaching the brain by targeting specific nerves.
• In 2019, Allergan received FDA approval for UBRELVY (ubrogepant) for the acute treatment of migraine. This is the first oral CGRP antagonist. This product approval has assisted the company to increase its revenue by increasing product sale.

North America Migraine Treatment Market Scope

The migraine treatment market is segmented on the basis of types of migraine, treatment, route of administration, product type, drug type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types of Migraine

• Episodic Migraine with Aura
• Chronic
• Others

Treatment

• Acute/Abortive Treatment
• Preventive/Prophylactic Treatment
• Non-Pharmacological Therapies and Devices

Route of Administration

• Oral
• Parenteral
• Nasal Sprays
• Others

Product Type

• Prescription
• Over The Counter

Drug Type

• Branded
• Generic

End-User

• • Hospitales y Clínicas
  • Laboratorios de diagnóstico
  • Otros

Análisis y perspectivas regionales sobre el tratamiento de la migraña

Se analiza el mercado de tratamiento de la migraña y se proporcionan información y tendencias del tamaño del mercado por tipo de migraña, tratamiento, vía de administración, tipo de producto, tipo de fármaco, usuario final y canal de distribución como se mencionó anteriormente.

Los países cubiertos en el informe del mercado de tratamiento de la migraña son Estados Unidos, Canadá y México en América del Norte.

Se espera que Estados Unidos lidere el mercado en el período de pronóstico de 2023 a 2030 debido a la gran cantidad de empresas que operan en el mercado, combinada con el creciente enfoque de las autoridades en la migraña en esta región. Además, el lanzamiento de nuevos medicamentos en el país también lo convierte en un mercado importante para los medicamentos de marca.  

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas arriba y aguas abajo, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de América del Norte y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.   

Análisis del panorama competitivo y de la cuota de mercado de tratamiento de la migraña en América del Norte

El panorama competitivo del mercado de tratamiento de la migraña proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia en América del Norte, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de tratamiento de la migraña.

Algunos de los principales actores que operan en el mercado del tratamiento de la migraña son:

• Pfizer Inc. (Estados Unidos)
• Lilly (Estados Unidos)
• Amgen Inc. (Estados Unidos)
• GSK plc. (Reino Unido)
• Novartis AG (Suiza)
• Bayer AG (Alemania)
• AbbVie Inc. (Estados Unidos)
• Abbott (Estados Unidos)
• Allodynic Therapeutics, LLC (Estados Unidos)
• AOBiome (Reino Unido)
• AstraZeneca (Reino Unido)
• Aurobindo Pharma (India)
• Bausch Health Companies Inc. (Canadá)
• Biohaven, Ltd. (Estados Unidos)
• Boehringer Ingelheim International GmbH (Alemania)
• Catalent, Inc. (Estados Unidos)
• Laboratorios Dr. Reddy Ltd. (India)
• Impel Pharmaceuticals Inc. (Estados Unidos)
• H. Lundbeck A/S (Dinamarca)
• Merck & Co., Inc (Estados Unidos)

SKU-54077